| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40765ca9a78b54a8a76f781d159ad145 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-664
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2016-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c23fed044a9225e3fa9dee2241f88f2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a4293c896e69222800f758bbd1cce4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02aa39d75e8daf6cd5abbb609048df1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3353a97b7adfcd143a8dfa5cf3b63a63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d38323c5a6e69744fbc18aa171dadc9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19b028a51f6ff66910ec872e9974d791
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c551f4fc60249445a8a7d3b8ae0fa7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3022198d8b84eff704b8286f00399f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_144d2d2095db7e1adbf635a8e50ab6e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6482acb6774b43bc969f0857504e572a |
| publicationDate |
2021-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
HR-P20160074-B1 |
| titleOfInvention |
PRODUCTS WHICH ARE PHOSPHONATE ANALYSIS OF NUCLEOTIDES AND METHODS OF THEIR SELECTION AND THEIR PREPARATION |
| abstract |
A new method for screening prodrugs of methoxyphosphonate nucleotide analogs for the identification of prodrugs that selectively target desired tissues and have antiviral or antitumor activity is presented. The method led to the identification of novel mixed PMPA ester-amidates for retroviral or hepadnavirus therapy, including compounds of structure (5a) having substituents as defined herein. Formulations of these novel compounds in pharmaceutically acceptable excipients and their use in therapy or prophylaxis are presented. An improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for local use is also shown. <BR/> <IMAGE NAME = "20160074_01" TYPE = "JPG" CENTER = TRUE /> A novel method is provided for screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. Also provided is an improved method for the use of magnesium alkoxide for the preparation of starting materials and compounds for use herein. |
| priorityDate |
2000-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |